NCT01702324

Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Fortuderm Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on plaque Psoriasis Vulgaris. The study will include subjects at plaque stage from 5-20% body area involvement. A total of 30 subjects will be treated with cream application on affected areas twice daily for three weeks.The efficacy of the preparation will be documented by PASI score, Global physician assessment and photos.

Detailed description

Psoriasis Vulgaris remains a widespread clinical entity with chronic outflares and various regimens of treatment, none of them definitive. A new safe and efficacious, external treatment is required for.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	DD-25	A topical DD-25 cream at 0.025% concentration.

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-08-01
• Completion: 2013-09-01
• First posted: 2012-10-08
• Last updated: 2012-10-08

Locations

1 site across 1 country: Israel